Roche to buy 89bio in deal worth up to $3.5B, picking up MASH drug The Swiss company said the 89bio candidate could complement its obesity pipeline (Sep 18, 2025) by Andrew Joseph. LONDON — Roche on Thursday said it would buy 89bio, the maker of an experimental drug for a liver disease that’s attracted increasing pharma interest, in a deal

Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate (Sep 8, 2025) by Darren Incorvaia. Servier is souping up its neurology pipeline with a clinical-stage candidate sourced from U.K. biotech Kaerus Bioscience for a rare genetic disease. The French pharma is offering as much as $450 million for KER-0193, a potential therapy for Fragile X syndrome. Kaerus

Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal (Aug 28, 2025) by Darren Incorvaia. As obesity pioneer Novo Nordisk loses ground in the race for next-generation drugs, the Danish pharma giant is betting on novel RNA technology to bolster its early-stage pipeline. Novo has inked a multiyear research collaboration with Replicate Bioscience, potentially

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (August 15, 2025) by Mariam E Sunny. Summary Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal’s lead candidate not part of deal with Lilly. Aug 14 (Reuters) – Eli Lilly (LLY.N), has signed a deal worth $1.3 billion with privately

Madrigal pens $2B pact for CSPC’s preclinical GLP-1 with eye on Rezdiffra MASH pairing (Jul 30, 2025) by James Waldron. Summary Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra The GLP-1 drug, dubbed SYH2086, has been developed by China’s CSPC Pharmaceutical. Preclinical

Novartis puts $1B on the line to court preclinical biotech Matchpoint (July 24, 2025) by Gabrielle Masson. Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor over the line for inflammatory diseases that have been historically difficult to treat. The exclusive option and licensing pact covers the development and commercialization

Lilly opens Gate to new small-molecule drug class with $856M biobucks deal (July 24, 2025) by Gabrielle Masson. Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small-molecule drug class. The pact’s potential value includes an undisclosed upfront payment amount and equity investment in the

Gensaic Announces Collaboration with Novo Nordisk to Unlock Next Generation Precision Therapies (March 03, 2025) by Novo Nordisk. Total deal value of up to $354 million in upfront, development, and commercial milestone payments per target plus tiered royalties; Novo Nordisk also will reimburse R&D costs and participate in future financing round Partnership leverages Gensaic’s proprietary FORGE™ engine for tissue-selective intracellular